Biotech · Private company · King Of Prussia, PA, US
Merlin Therapeutics Inc
Track this companyFree. Adds Merlin Therapeutics Inc to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards3
- AAV-mediated delivery of the inflammasome adapter protein, ASC, as a pro-apoptotic gene therapy for schwannomaFiscal year 2026 · $1.5MNIH RePORTER 5R44NS145814-02 · fetched Nov 12, 2026
- AAV-mediated delivery of the inflammasome adapter protein, ASC, as a pro-apoptotic gene therapy for schwannomaFiscal year 2025 · $1.3MNIH RePORTER 1R44NS145814-01 · fetched Nov 12, 2026
- Development of a Novel AAV9 Gene Replacement Therapy for Neurofibromatosis Type 2Fiscal year 2024 · $699.6KNIH RePORTER 1R41NS135883-01 · fetched Nov 12, 2026